News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
244,767 Results
Type
Article (5864)
Company Profile (20)
Press Release (238883)
Section
Business (87770)
Career Advice (471)
Deals (16496)
Drug Delivery (10)
Drug Development (21316)
Employer Resources (32)
FDA (4066)
Job Trends (4553)
News (129964)
Policy (8427)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (2)
2025 Lone Star Bio Digital (1)
Academia (337)
Adcomms (3)
Allergies (9)
Alliances (16249)
ALS (19)
Alzheimer's disease (308)
Antibody-drug conjugate (ADC) (12)
Approvals (4082)
Artificial intelligence (46)
Autoimmune disease (4)
Automation (2)
Bankruptcy (107)
Best Places to Work (3389)
Biosimilars (12)
Biotechnology (28)
Bladder cancer (11)
Brain cancer (8)
Breast cancer (65)
Cancer (484)
Cardiovascular disease (22)
Career advice (401)
Career pathing (2)
CAR-T (30)
Cell therapy (106)
Cervical cancer (2)
Clinical research (17784)
Collaboration (181)
Compensation (145)
Complete response letters (3)
COVID-19 (453)
CRISPR (7)
C-suite (93)
Cystic fibrosis (19)
Data (542)
Depression (7)
Diabetes (43)
Diagnostics (2253)
Digital health (3)
Diversity, equity & inclusion (13)
Drug discovery (26)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (12)
Earnings (42653)
Editorial (1)
Employer branding (6)
Employer resources (33)
Events (40376)
Executive appointments (296)
FDA (4313)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (213)
Gene editing (16)
Generative AI (2)
Gene therapy (47)
GLP-1 (119)
Government (505)
Guidances (16)
Healthcare (5572)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (13)
Indications (6)
Infectious disease (471)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (57)
IPO (8394)
IRA (3)
Job creations (1261)
Job search strategy (366)
Kidney cancer (6)
Labor market (4)
Layoffs (108)
Leadership (4)
Legal (2677)
Liver cancer (18)
Lung cancer (55)
Lymphoma (27)
Management (11)
Manufacturing (52)
MASH (26)
Medical device (4300)
Medtech (4302)
Mergers & acquisitions (8318)
Metabolic disorders (118)
Multiple sclerosis (12)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (2)
Neuroscience (408)
NextGen: Class of 2025 (1794)
Non-profit (791)
Northern California (874)
Now hiring (2)
Obesity (51)
Opinion (32)
Ovarian cancer (17)
Pain (15)
Pancreatic cancer (19)
Parkinson's disease (21)
Partnered (8)
Patents (27)
Patient recruitment (27)
Peanut (5)
People (26381)
Pharmaceutical (8)
Pharmacy benefit managers (1)
Phase I (5270)
Phase II (7835)
Phase III (6129)
Pipeline (497)
Policy (4)
Postmarket research (662)
Preclinical (2084)
Press Release (67)
Prostate cancer (28)
Psychedelics (5)
Radiopharmaceuticals (120)
Rare diseases (69)
Real estate (2014)
Recruiting (9)
Regulatory (5629)
Reports (15)
Research institute (351)
Resumes & cover letters (68)
Rett syndrome (2)
Schizophrenia (24)
Series A (27)
Series B (21)
Service/supplier (2)
Sickle cell disease (8)
Southern California (673)
Special edition (1)
Spinal muscular atrophy (30)
Sponsored (4)
Startups (1124)
State (1)
Stomach cancer (1)
Supply chain (11)
United States (7094)
Vaccines (59)
Venture capitalists (3)
Webinars (5)
Weight loss (19)
Women's health (1)
Date
Today (49)
Last 7 days (225)
Last 30 days (919)
Last 365 days (11435)
2025 (2660)
2024 (12221)
2023 (14533)
2022 (20457)
2021 (21868)
2020 (19720)
2019 (14316)
2018 (11015)
2017 (10883)
2016 (10015)
2015 (13180)
2014 (10375)
2013 (8370)
2012 (9066)
2011 (9474)
2010 (9291)
Location
Africa (200)
Alabama (14)
Alaska (2)
Arizona (65)
Arkansas (1)
Asia (12162)
Australia (1665)
California (1842)
Canada (1018)
China (72)
Colorado (84)
Connecticut (95)
Delaware (30)
Europe (25962)
Florida (257)
Georgia (37)
Idaho (23)
Illinois (111)
India (5)
Indiana (74)
Iowa (1)
Japan (69)
Kansas (25)
Kentucky (11)
Louisiana (5)
Maine (38)
Maryland (215)
Massachusetts (1504)
Michigan (104)
Minnesota (140)
Mississippi (1)
Missouri (21)
Montana (16)
Nebraska (14)
Nevada (24)
New Hampshire (23)
New Jersey (659)
New Mexico (8)
New York (493)
North Carolina (337)
North Dakota (2)
Northern California (874)
Ohio (54)
Oklahoma (7)
Oregon (3)
Pennsylvania (362)
Puerto Rico (1)
Rhode Island (15)
South America (310)
South Carolina (4)
Southern California (673)
Tennessee (38)
Texas (254)
Utah (60)
Virginia (39)
Washington D.C. (8)
Washington State (165)
West Virginia (2)
Wisconsin (29)
244,767 Results for "angion biomedica corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the closing of its previously announced merger with Angion Biomedica Corp.
June 1, 2023
·
8 min read
Business
Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica
Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company.
January 17, 2023
·
1 min read
·
Hayley Shasteen
Genetown
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
Angion Biomedia Corp., a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.
June 1, 2023
·
2 min read
Deals
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.
January 17, 2023
·
11 min read
Policy
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Angion Biomedica Corp announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450.
December 21, 2022
·
3 min read
Pharm Country
Angion Announces Participation in Upcoming Investment Conference - May 12, 2022
Angion Biomedica Corp. announced participation in an upcoming investment conference.
May 12, 2022
·
1 min read
Business
Oxford Biomedica Business Update
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces a business update for the year ending 31 December 2023.
December 7, 2023
·
6 min read
Deals
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).
January 29, 2024
·
4 min read
Business
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results
Angion Biomedica Corp provided a corporate update and reported its financial results for the quarter ended March 31, 2022.
May 16, 2022
·
8 min read
Drug Development
Angion Ends Kidney Disease Trial while Novo Hits NASH Wall
Angion Biomedica Corp. discontinued a Phase II kidney disease trial while Novo Nordisk missed the mark in a NASH study.
June 30, 2022
·
3 min read
·
Alex Keown
1 of 24,477
Next